Univest
Univest
  • Markets

Narayana Hrudayalaya vs KIMS 2027: Similar Market Value, but a P/E of 45 Against 164

  • November 20, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Narayana Hrudayalaya vs KIMS 2027: Similar Market Value, but a P/E of 45 Against 164
Narayana Hrudayalaya vs KIMS at a glance Narayana Hrudayalaya Krishna Institute of Medical Sciences
Share price (19 Nov 2026) Rs 1,873.10 Rs 767.80
Market cap Rs 38,297 crore Rs 32,301 crore
P/E ratio 44.58 163.98
Q2 FY27 net profit Rs 301.1 crore Rs 74.6 crore

Quick Answer

Narayana Hrudayalaya vs KIMS compares two fast-expanding Indian hospital chains that are close in market value but far apart on earnings. Narayana Hrudayalaya is valued at about Rs 38,297 crore and Krishna Institute of Medical Sciences (KIMS) at about Rs 32,301 crore. In Q2 FY27, Narayana’s revenue rose 73.6% and net profit 16.5% to Rs 301 crore, while KIMS’s revenue rose 41.3% and net profit 3.6% to Rs 75 crore. Narayana trades at a P/E of 44.58 against 163.98 for KIMS.

Narayana Hrudayalaya vs KIMS in 2027 is a lesson in how expansion affects valuation: the two chains have similar market values, but Narayana trades at 44.58 times earnings while KIMS trades at 163.98 times, because new hospitals have pushed KIMS’s profit down. The Narayana Hrudayalaya vs KIMS hospital expansion story explains most of the gap.

Both stocks trade about 10.5% below their 52-week highs and are measured within the broader Nifty 500. This Narayana Hrudayalaya vs KIMS guide compares their business models, valuation, Q2 FY27 results, expansion plans, risks and shareholding.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Narayana Hrudayalaya vs KIMS: Company Overview
    • What Narayana Hrudayalaya Does
    • What Krishna Institute of Medical Sciences Does
  • How Narayana Hrudayalaya and KIMS Make Money
  • Narayana Hrudayalaya vs KIMS Valuation and Key Metrics
  • Narayana Hrudayalaya vs KIMS Q2 FY27 Results
  • Narayana Hrudayalaya vs KIMS Hospital Expansion in 2027
    • Narayana: scale and integration
    • KIMS: new hospitals maturing
  • Risks in Narayana Hrudayalaya vs KIMS
    • Risks for Narayana Hrudayalaya
    • Risks for Krishna Institute of Medical Sciences
  • Narayana Hrudayalaya vs KIMS Shareholding
  • Which Investor Does Each Hospital Stock Suit?
    • Narayana Hrudayalaya suits investors who want earnings-backed growth
    • KIMS suits investors betting on new hospitals maturing
  • Final View on Narayana Hrudayalaya vs KIMS
  • FAQs on Narayana Hrudayalaya vs KIMS
    • Why is KIMS's P/E so much higher than Narayana's?
    • How did Narayana Hrudayalaya perform in Q2 FY27?
    • How did KIMS perform in Q2 FY27?
    • Which hospital chain has the higher ROE?
    • Which company is larger?
    • How far are both stocks from their 52-week highs?
    • Is Narayana Hrudayalaya vs KIMS a buy or sell decision?

Narayana Hrudayalaya vs KIMS: Company Overview

What Narayana Hrudayalaya Does

Narayana Hrudayalaya, founded by cardiac surgeon Dr Devi Shetty, runs a network of multi-speciality hospitals across India and a hospital in the Cayman Islands. It is known for high-volume, affordable tertiary care. Promoters hold 63.27%.

What Krishna Institute of Medical Sciences Does

Krishna Institute of Medical Sciences (KIMS), based in Hyderabad, runs multi-speciality hospitals across Telangana and Andhra Pradesh and has been expanding into Maharashtra, Karnataka and Kerala. Promoters hold 32.66%.

How Narayana Hrudayalaya and KIMS Make Money

Both earn from inpatient treatment, surgeries, outpatient care and diagnostics. Mature hospitals earn steady margins, while new hospitals usually lose money for a few years until occupancy builds up.

Both are in expansion mode. Narayana’s revenue jump reflects a larger hospital base, including acquisitions, while KIMS has opened several new hospitals in new states, which is weighing on its profit.

Narayana Hrudayalaya vs KIMS Valuation and Key Metrics

These figures use the 19 November 2026 close and trailing twelve month ratios.

Narayana Hrudayalaya vs KIMS metric Narayana Hrudayalaya Krishna Institute of Medical Sciences
Share price (CMP) Rs 1,873.10 Rs 767.80
52-week high Rs 2,092.90 Rs 858.00
52-week low Rs 1,589.00 Rs 575.80
Distance from 52-week high -10.5% -10.5%
Market capitalisation Rs 38,297 crore Rs 32,301 crore
P/E ratio (TTM) 44.58 163.98
Industry P/E 63.67 63.67
P/B ratio 7.65 8.22
Return on equity (ROE) 17.17% 5.40%
Debt to equity 1.21 0.90
Dividend yield 0.24% 0.00%
FY26 revenue Rs 7,996 crore Rs 3,931 crore
FY26 net profit Rs 810.5 crore Rs 242.0 crore

The Narayana Hrudayalaya vs KIMS table shows Narayana trading at a P/E of 44.58 against 163.98 for KIMS. The hospital industry P/E is 63.67, so Narayana trades below the sector and KIMS far above it.

Narayana has a much higher return on equity at 17.17% against 5.40%. Both carry debt to fund expansion, with debt to equity of 1.21 for Narayana and 0.90 for KIMS.

Both are about 10.5% below their 52-week high levels. Narayana closed at Rs 1,873.10 against a high of Rs 2,092.90, and KIMS at Rs 767.80 against a high of Rs 858.

Narayana Hrudayalaya vs KIMS Q2 FY27 Results

Figures below are consolidated revenue and net profit for the quarter ended 30 September 2026.

Narayana Hrudayalaya vs KIMS Q2 FY27 (Sep 2026 quarter) Narayana Hrudayalaya Krishna Institute of Medical Sciences
Revenue Q2 FY27 Rs 2,896 crore Rs 1,363 crore
Revenue Q2 FY26 Rs 1,668 crore Rs 964.9 crore
Revenue change YoY +73.6% +41.3%
Net profit Q2 FY27 Rs 301.1 crore Rs 74.6 crore
Net profit Q2 FY26 Rs 258.5 crore Rs 72.0 crore
Net profit change YoY +16.5% +3.6%
Net profit Q1 FY27 Rs 207.3 crore Rs 37.4 crore

In the Q2 FY27 results, Narayana’s revenue rose 73.6% to Rs 2,895.5 crore and net profit rose 16.5% to Rs 301.2 crore. Its operating margin eased to 21.2% from 25.9%, and profit grew from Rs 207.3 crore in the June quarter.

KIMS’s revenue rose 41.3% to Rs 1,363 crore and net profit rose 3.6% to Rs 74.6 crore. Its operating margin held at 21.7%, and profit doubled from Rs 37.4 crore in Q1 FY27.

In the quarter, both grew revenue far faster than profit, as new capacity added costs before earnings.

Narayana Hrudayalaya vs KIMS Hospital Expansion in 2027

Narayana: scale and integration

Narayana’s FY26 revenue rose 43.4% to Rs 7,996 crore while net profit rose 2.6% to Rs 810.5 crore. Integrating its expanded network and lifting margins back toward earlier levels is its main task for 2027.

KIMS: new hospitals maturing

KIMS’s FY26 revenue rose 28.2% to Rs 3,931 crore, but net profit fell 41.7% to Rs 242 crore as new hospitals added costs. As these hospitals fill up, profit could recover sharply, which is what its high P/E is pricing in.

In the Narayana Hrudayalaya vs KIMS hospital expansion race, KIMS carries more near-term execution risk, while Narayana has the stronger current earnings base.

Compare hospital stocks on the Univest Screener

Risks in Narayana Hrudayalaya vs KIMS

Risks for Narayana Hrudayalaya

Narayana’s main risks are integrating acquired hospitals, margin pressure and higher debt. Foreign institutions cut their stake from 10.49% to 9.01%.

Risks for Krishna Institute of Medical Sciences

In the Narayana Hrudayalaya vs KIMS risk check, KIMS’s main risk is that new hospitals take longer to break even. A P/E of 163.98 leaves very little room for delays. Promoters trimmed their stake from 34.11% to 32.66%.

Narayana Hrudayalaya vs KIMS Shareholding

Narayana Hrudayalaya vs KIMS shareholding (Sep ’26, change vs Sep ’25) Narayana Hrudayalaya Krishna Institute of Medical Sciences
Promoters 63.27% (-0.58 pts) 32.66% (-1.45 pts)
Foreign institutions (FII) 9.01% (-1.48 pts) 15.01% (-0.02 pts)
Domestic institutions (DII) 10.68% (+2.92 pts) 32.30% (+0.18 pts)
Public and others 17.04% (-0.86 pts) 20.03% (+1.29 pts)

Narayana promoters hold 63.27%. Domestic institutions raised their stake from 7.76% to 10.68%.

KIMS promoters hold 32.66%. Domestic institutions hold 32.30% and foreign institutions 15.01%, both little changed. KIMS has a much larger institutional base.

Download the Univest iOS App or Univest Android App to track Narayana Hrudayalaya and KIMS live and follow healthcare research.

Which Investor Does Each Hospital Stock Suit?

Narayana Hrudayalaya suits investors who want earnings-backed growth

Within Narayana Hrudayalaya vs KIMS, Narayana fits investors who want a hospital chain with a P/E below the sector and an ROE above 17%. They need to accept integration and debt risks.

KIMS suits investors betting on new hospitals maturing

KIMS fits investors who expect its new hospitals to drive a sharp profit recovery. They need to accept a very high P/E today.

Final View on Narayana Hrudayalaya vs KIMS

Narayana Hrudayalaya vs KIMS pairs two expanding hospital chains with similar market values. Narayana earns more, with an ROE of 17.17% and a P/E of 44.58. KIMS’s profit is depressed by new hospitals, which leaves it at 163.98 times earnings.

The Narayana Hrudayalaya vs KIMS outlook for 2027 depends on how quickly new capacity turns profitable. Occupancy and margins are the numbers to watch.

Disclaimer: Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Narayana Hrudayalaya vs KIMS

Why is KIMS's P/E so much higher than Narayana's?

Ans. KIMS trades at a P/E of 163.98, compared with 44.58 for Narayana Hrudayalaya. KIMS's FY26 profit fell 41.7% to Rs 242 crore as new hospitals added costs. The market expects profit to recover as these hospitals mature. The hospital industry P/E is 63.67.

How did Narayana Hrudayalaya perform in Q2 FY27?

Ans. Narayana's revenue rose 73.6% to Rs 2,895.5 crore and net profit rose 16.5% to Rs 301.2 crore in Q2 FY27. Its operating margin eased to 21.2% from 25.9%. Profit grew from Rs 207.3 crore in the June quarter. A larger hospital base drove revenue growth.

How did KIMS perform in Q2 FY27?

Ans. KIMS's revenue rose 41.3% to Rs 1,363 crore and net profit rose 3.6% to Rs 74.6 crore in Q2 FY27. Its operating margin was 21.7%. Profit doubled from Rs 37.4 crore in the June quarter. New hospitals continue to weigh on earnings.

Which hospital chain has the higher ROE?

Ans. Narayana Hrudayalaya has a return on equity of 17.17%, compared with 5.40% for KIMS. Narayana's mature hospitals earn steady returns. KIMS's ROE is low because of new hospital costs. Both companies carry debt for expansion.

Which company is larger?

Ans. Narayana Hrudayalaya has a market cap of about Rs 38,297 crore, compared with Rs 32,301 crore for KIMS. Narayana's FY26 revenue was Rs 7,996 crore against Rs 3,931 crore for KIMS. Narayana's FY26 net profit was Rs 810.5 crore and KIMS's was Rs 242 crore. Their market values are closer than their earnings.

How far are both stocks from their 52-week highs?

Ans. Narayana closed at Rs 1,873.10 on 19 November 2026, about 10.5% below its 52-week high of Rs 2,092.90. KIMS closed at Rs 767.80, also about 10.5% below its high of Rs 858. Narayana's 52-week low is Rs 1,589 and KIMS's is Rs 575.80. Prices change daily.

Is Narayana Hrudayalaya vs KIMS a buy or sell decision?

Ans. This Narayana Hrudayalaya vs KIMS comparison is educational and does not give a buy or sell call. Narayana offers earnings-backed growth at a lower P/E, while KIMS offers a recovery case at a very high P/E. Both carry expansion risk. Investors should consult a SEBI-registered adviser before acting.



2027 hospitals Krishna Institute of Medical Sciences Narayana Hrudayalaya Stock Comparison
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply